Citation:Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, et al 2013

From Cancer Guidelines Wiki

Citation


Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst 2013 May 15;105(10):719-25 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23479454.


This is a publication of ERSPC

Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?Tracy Tsangcompleted
For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?Suzanne Hughescompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Discussion
  2. ERSPC
  3. PSA Testing strategies